Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Interpace Biosciences Inc is a diagnostics & research business based in the US. Interpace Biosciences shares (IDXG) are listed on the OTCQX (a marketplace for buying and selling "over the counter" stocks which aren't listed on a formal stock exchange) and all prices are listed in US Dollars. Interpace Biosciences employs 147 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $3.20 |
|---|---|
| 52-week range | $2.76 - $10.50 |
| 50-day moving average | $3.54 |
| 200-day moving average | $5.91 |
| Wall St. target price | $11.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-3.12 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.2 from 2022-07-01
| 1 week (2022-06-28) | -4.48% |
|---|---|
| 1 month (2022-06-06) | -11.11% |
| 3 months (2022-04-06) | -36.00% |
| 6 months (2022-01-06) | -62.35% |
| 1 year (2021-07-06) | -68.63% |
|---|---|
| 2 years (2020-07-06) | -49.69% |
| 3 years (2019-07-05) | 350.70% |
| 5 years (2017-07-05) | 232.54% |
| Revenue TTM | $41.9 million |
|---|---|
| Gross profit TTM | $17.9 million |
| Return on assets TTM | -16.91% |
| Return on equity TTM | -161.49% |
| Profit margin | -31.02% |
| Book value | $0.42 |
| Market capitalisation | $14.5 million |
TTM: trailing 12 months
We're not expecting Interpace Biosciences to pay a dividend over the next 12 months.
Interpace Biosciences's shares were split on a 1:10 basis on 14 January 2020. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Interpace Biosciences shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Interpace Biosciences shares which in turn could have impacted Interpace Biosciences's share price.
Over the last 12 months, Interpace Biosciences's shares have ranged in value from as little as $2.755 up to $10.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (OTCQX average) beta is 1, while Interpace Biosciences's is 1.2872. This would suggest that Interpace Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc.
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.